Positive Updated Results from Disc Medicine’s Phase 1b Trial in Patients with [Condition]
Disc Medicine recently shared some exciting news about their Phase 1b trial for patients with myelofibrosis and anemia. The study, presented at the 2024 American Society of Hematology conference, revealed that their treatment, DISC-0974, made significant improvements in patient’s hepcidin levels and iron levels, resulting in better outcomes for those with anemia.
John Quisel, Disc Medicine’s President and CEO, expressed enthusiasm about the trial results, highlighting the positive impact of DISC-0974 in reducing transfusion burdens and increasing hemoglobin levels. The study showed consistent improvements across all patient subgroups, regardless of baseline transfusion status or concurrent use of JAK inhibitors.
Building on this success, Disc Medicine has launched a Phase 2 trial to further investigate the potential of DISC-0974 in treating myelofibrosis patients with anemia. This new study aims to enroll a diverse range of patient types to continue exploring the benefits of this promising treatment.
This expanded data set from the Phase 1b trial is a significant step forward in the development of novel treatments for serious hematologic diseases. Disc Medicine’s commitment to innovative research and patient care is reflected in the promising results of DISC-0974, offering hope to those affected by MF and anemia.
